15 results about "Dopaminergic Agonists" patented technology

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in treating conditions for which treatment with a dopamine agonist has therapeutic benefit, and pharmaceutical compositions comprising a compound of the present invention. The compounds according to the present invention have the formula (Id), wherein R1and R2are each independently selected from H and the substituent (iii) below, wherein * indicates the point of attachment to oxygen, wherein R3is selected from H and COR4, and wherein R4is selected from H and C1-C6alkyl, with the proviso that R1and R2cannot both be H, 15or a pharmaceutically acceptable salt thereof.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

Compositions and methods for treating neurological conditions are provided. The present invention provides a pharmaceutical composition comprising a dopamine reuptake inhibitor or dopamine agonist, an adrenergic receptor antagonist, and a pharmaceutically acceptable carrier, and a method for treating a neurological disorder by administering the composition.

The present invention relates to methods and devices for providing a treatment recommendation based on a prediction of at least one Impulse Control Disorder occurrence for a patient undergoing a treatment with Dopamine Agonists.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

1. The name of the design product: long handle hair stick (Dopamine). 2. The use of the design product: for hair stick. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

This invention discloses a novel method for detecting isomer impurities in dopamine agonists. The method employs high-performance liquid chromatography (HPLC), using a cyclodextrin-packed column, with sodium perchlorate buffer as mobile phase A and acetonitrile as mobile phase B. The test solution is injected into the HPLC system for isocratic elution. This invention overcomes the technical bias of requiring forward chromatography for isomer detection and separation, creatively exploring a method for analyzing and detecting isomer impurities in pramipexole hydrochloride tablets using reverse chromatography. The method offers advantages such as high specificity, high accuracy, good durability, and low reagent hazard, effectively filling a gap in the quality standards for pramipexole hydrochloride tablets. It provides a technical reference for the quality control of pramipexole hydrochloride tablets, ensuring medication safety.

The invention provides a novel pharmaceutical composition comprising a phosphodiesterase type 5 (PDE5) inhibitor other than sildenafil and a dopamine agonist and method of use thereof for treating erectile dysfunction and / or male hypogonadism.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson’s disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The present invention relates to the use of nicotinic acetylcholine receptor alpha 7 activators, in particular to the use of nicotinic acetylcholine receptor alpha 7 agonists for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.